Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Accounts Payable
Zealand Pharma A/S
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Accounts Payable
kr254.8m
|
CAGR 3-Years
58%
|
CAGR 5-Years
35%
|
CAGR 10-Years
30%
|
|
|
Genmab A/S
CSE:GMAB
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Accounts Payable
€96.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
28%
|
CAGR 10-Years
34%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Accounts Payable
kr1B
|
CAGR 3-Years
58%
|
CAGR 5-Years
56%
|
CAGR 10-Years
33%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Accounts Payable
kr5.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
|
Saniona AB
STO:SANION
|
Accounts Payable
kr17.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
23%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Accounts Payable?
Accounts Payable
254.8m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Accounts Payable amounts to 254.8m DKK.
What is Zealand Pharma A/S's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
30%
Over the last year, the Accounts Payable growth was 24%. The average annual Accounts Payable growth rates for Zealand Pharma A/S have been 58% over the past three years , 35% over the past five years , and 30% over the past ten years .
You don't have any saved screeners yet